Pretty simple even for a layperson. The bavi arm is performing as expected but will not meet the assumptions tha it would beat the control arms to the extent expected. This I's due to control arm overachieving their expected results. Most likely due to there being new third line I/O drugs for control group to opt for after being told they are progressing
"The interim analysis results demonstrated that the bavituximab plus docetaxel combination group is unlikely to achieve the assumptions established at the initiation of the trial." This is the assumed separation from the control group...ie looking at both arms and trial assumptions.
"This analysis also showed that the bavituximab combination group is performing as expected according to the original trial assumptions in terms of overall survival........"
Market Data 
Markets 
AI
